SATVI receives accreditation as UCT research site
The South African Tuberculosis Vaccine Initiative (SATVI) is an accredited UCT Research Site which offers major benefits to the organisation, including improved governance environment, five-yearly cycle of strategic review, and the potential to leverage additional funding for students and post-doctoral fellows. SATVI recently published the findings of the first efficacy trial of a new infant TB vaccine (MVA85A) in almost 50 years (Tameris/Hatherill, Lancet 2013). This groundbreaking clinical trial brought the group to international prominence and secured its position as the preferred clinical trial partner to test the safety, immunogenicity, and efficacy of new TB vaccines in the development pipeline.
SATVI’s academic and administrative hub, and state-of-the-art immunology laboratory, lie within the Institute of Infectious Disease & Molecular Medicine (IDM) of the Faculty of Health Sciences, and are complemented by extensive clinical and laboratory facilities at the SATVI field site in Worcester, 110km from Cape Town.